BeiGene, Ltd. (ONC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
BeiGene, Ltd. stock (ONC) is currently trading at $283.45. BeiGene, Ltd. PE ratio is 111.00. BeiGene, Ltd. PS ratio (Price-to-Sales) is 5.92. Analyst consensus price target for ONC is $411.05. WallStSmart rates ONC as Sell.
- ONC PE ratio analysis and historical PE chart
- ONC PS ratio (Price-to-Sales) history and trend
- ONC intrinsic value — DCF, Graham Number, EPV models
- ONC stock price prediction 2025 2026 2027 2028 2029 2030
- ONC fair value vs current price
- ONC insider transactions and insider buying
- Is ONC undervalued or overvalued?
- BeiGene, Ltd. financial analysis — revenue, earnings, cash flow
- ONC Piotroski F-Score and Altman Z-Score
- ONC analyst price target and Smart Rating
BeiGene,
📊 No data available
Try selecting a different time range
ONC Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · BeiGene, Ltd. (ONC)
ONC trades 1983% above its Graham fair value of $16.86, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
BeiGene, Ltd. (ONC) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, revenue growth. Concerns around return on equity and price/book. Mixed signals suggest waiting for clearer direction before acting.
BeiGene, Ltd. (ONC) Key Strengths (2)
Revenue surging 32.80% year-over-year
Large-cap company with substantial market presence
Supporting Valuation Data
BeiGene, Ltd. (ONC) Areas to Watch (6)
Very expensive at 7.0x book value
Low profitability relative to shareholder equity
Thin operating margins with cost pressures present
Premium valuation at 5.9x annual revenue
Thin profit margins with limited profitability
Moderate institutional interest at 32.01%
Supporting Valuation Data
BeiGene, Ltd. (ONC) Detailed Analysis Report
Overall Assessment
This company scores 40/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.5/10) while 6 fall into concern territory (avg 3.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Market Cap. Growth metrics are encouraging with Revenue Growth at 32.80%.
The Bear Case
The primary concerns are Price/Book, Return on Equity, Operating Margin. Some valuation metrics including Price/Sales (5.92), Price/Book (7.01) suggest expensive pricing. Profitability pressure is visible in Return on Equity at 7.46%, Operating Margin at 12.30%, Profit Margin at 5.37%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 7.46% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 32.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Price/Book and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ONC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ONC's Price-to-Sales ratio of 5.92x trades at a deep discount to its historical average of 52.63x (4th percentile). The current valuation is 99% below its historical high of 578.06x set in Sep 2017, and 10% above its historical low of 5.38x in Jun 2024. Over the past 12 months, the PS ratio has compressed from ~7.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for BeiGene, Ltd. (ONC) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
BeiGene, Ltd. is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 5.3B with 33% growth year-over-year. Profit margins are thin at 5.4%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Revenue growing at 33% YoY, reaching 5.3B. This pace significantly outperforms most BIOTECHNOLOGY peers.
Generating 131M in free cash flow and 417M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can BeiGene, Ltd. push profit margins above 15% as the business scales?
Growth sustainability: can BeiGene, Ltd. maintain 33%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 111.0x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact BeiGene, Ltd..
Bottom Line
BeiGene, Ltd. is a high-conviction growth story with revenue accelerating at 33% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 5.4% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 11:40:14 AM
About BeiGene, Ltd.(ONC)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.